arrow
I

In Hae Park

seoul national university
H指数:36
被引数:5,998

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies

曲妥珠单抗-pkrb联合吉地洛昔布在HER2阳性转移性乳腺癌患者中的II期研究,该患者在接受两种或更多HER2靶向治疗后进展

2026-07-011
OAAI
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)

MIRINAE试验(一项比较辅助阿替利珠单抗联合卡培他滨与单用卡培他滨的随机II期试验;KCSG-BR18-21)中,新辅助化疗后残留浸润性三阴性乳腺癌的基因组学和转录组学分析

2025-09-240
PREAI
Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)

韩国全国范围内帕博西利(palbociclib)在HR(+)、HER2(−)转移性乳腺癌患者中的真实世界实践模式与临床数据(KCSG BR21-15)

2025-05-120
OA
Comparison of clinical efficacy between letrozole plus ribociclib vs. Fulvestrant plus letrozole plus ribociclib in Hormone receptor positive, HER2 negative metastatic breast cancer - a randomized, phase 2 study (KCSG BR22-20)
2024-05-020
PRE
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
2024-01-280
OAAI
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer
2023-11-225
OAAI
Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study
2023-03-010
PRE
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group

基于电子病历的真实世界数据的数据收集框架,以评估癌症药物的有效性和安全性: 韩国癌症研究小组的一项全国性真实世界研究

2022-11-022
OAAI
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)
BREAST
IF7.9
2022-10-012
OAAI
A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG BR19-15)
2022-02-150
PRE